The Impact of Mobile Health on Patient-Centric Disease Management -





Published: August 2013 | Pages: 103 | Format: PDF

 Report Overview 

 Banks use them. So does the travel industry. And tastemakers are harnessing their power every day. Now, it’s pharma’s turn to explore mobile and digital apps. 

 In an age where patients are well-informed and thus have a stronger-than-ever sense of ownership over their disease, there is mounting evidence that mobile health apps are affecting outcomes. Well-designed and intuitive, health apps can helping clinicians and healthcare providers better manage treatments, even after they leave the consulting rooms. As a result, patient adherence can improve. 

 So what’s in it for the pharmaceutical industry? Better health outcomes mean improved market access and greater brand loyalty. What’s more, as pharma taps into the mobile health industry—set to grow to US$30 billion in three years, according to some estimates—real world data looped back from platforms will have far-reaching implications for drug development and clinical trials. 

 Through The Impact of Mobile Health on Patient-Centric Disease Management, FirstWord explores the emerging and exciting world of mobile and digital health apps. Based on interviews from nine industry experts, reviews of clinical and commercial opportunities and case studies, the report offers insight into app development, integration, and how the industry can capture the market now and in the future. 

 Key Report Features of The Impact of Mobile Health on Patient-Centric Disease Management include: 

 

  •  Expert opinion from those working at the forefront of the emerging mHealth industry, including experts from GlaxoSmithKline, Boehringer Ingelheim, UCB and Janssen Healthcare 
  •  Overview of clinical and commercial opportunities and realities. with implications for patients, clinicians and pharma 
  •  Case studies of new, established and successful platforms, covering diabetes, schizophrenia, adherence, cognitive behavioural therapy and epilepsy 
  •  Insight into the use of data for clinical patient management 

 

 Key Benefits 

 While mobile and digital health apps are relatively new to pharma, there are clear signs they present excellent opportunities for the industry. In The Impact of Mobile Health on Patient-Centric Disease Management, FirstWord explores this exciting new area. Amongst the benefits, this report will help you to: 

 

  •  Understand the parameters of the booming mobile app business, as it applies to pharma 
  •  Learn the critical path for development of apps, platforms, gamification and optimising patient engagement 
  •  Understand how real world data gathered can make a difference in drug development and meeting demands for data from regulators and reimbursement agencies 
  •  Develop key knowledge about how mobile, digital and healthcare industries will grow together 

 

 The Impact of Mobile Health on Patient-Centric Disease Management answers key questions: 

 

  •  How can pharma harness the mobile and digital app industry? 
  •  What returns can pharma expect by developing mobile and digital apps? 
  •  What are the most successful apps to date and what garnered their success? 
  •  What are the key benefits of mobile technology for pharma, patients and physicians? 
  •  What is the future of digital and mobile health apps? 

 

 Selected Quotes 

 “Use of these platforms means that patients are taking responsibility for themselves; that’s the magic bullet in a way, and that gets a win for everyone.” David Proudlock, GSK 

 “Effectively, the healthcare professional or other stakeholder starts to have a better view of the patient’s clinical management outside of the consulting room, helping to prevent events, and enabling the provision of care for patients remotely. It’s a very different experience for patients, but it’s certainly something that patients tell us they want to see happen.” Michael Morgan-Curran from the GSMA 

 “If we say to a payer, we have a drug but we also have a proven and remote monitoring device through a partner company so when a patient gets the drug they also get the mobile health device or app and we have proven studies, then we might be in a preferential position compared to a competitor molecule. We would have a better position from a market access perspective.” Wolfgang Renz, Boehringer Ingelheim 

 Expert Views 

 

  •  Larry Brooks, Director, Business Model & Healthcare Innovation at Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) 
  •  Tony Free, developer of iThinkSmarter smartphone app and cognitive behavioural therapist, Yorkshire, UK 
  •  Graham Howieson, CEO at GP Solutions (UK) Ltd, in Manchester, UK 
  •  Navin Joshi, Senior Director, Customer Solutions in Access to Medicines at GlaxoSmithKline 
  •  Marco Mohwinckel, partner at Janssen Healthcare Innovation, Europe, Middle East and Africa 
  •  Michael Morgan-Curran, Global Director of mHealth & Diabetes Programme Director at the GSMA (GSM Association) 
  •  Roger Palframan, Head of Innovation Super Networks at UCB 
  •  David Proudlock, Director, Innovation and Disruptive Technologies - UK Pharma at GlaxoSmithKline 
  •  Wolfgang Renz, Corporate Vice President, Business Model & Healthcare Innovation, Boehringer Ingelheim based in the U.S 

 

 Content Highlights 

 Mobile and digital health apps are being developed with great success in pockets of the industry. In this report, you will discover: 

 

  •  The importance of digital platforms and mobile apps in providing integrated health solutions 
  •  The hidden value of mobile apps in collating, distributing and analysing real world data 
  •  The current state-of-play for regulations, leading up to the FDA’s pending guidance on mobile apps 

 

 Executive summary  

 Real world data  

 Regulatory approval of mobile health devices  

 Telecommunications operators  

 Moving into the mobile and digital health space.  

 Methodology  

 Introduction  

 Terminology  

 Opportunity for pharmaceutical industry involvement.  

 Mobile health and digital health platforms: their importance to patients, physicians and the pharmaceutical industry  

 What is meant by ‘mobile health'?  

 The benefits of mobile health across the entire patient care pathway  

 Holistic health: the importance of engaging and empowering the whole patient through mobile health solutions  

 Disease management: patients in the driving seat  

 Patient-initiated responses have positive implications for clinical care and healthcare resources/systems  

 Availability of mobile health platforms for patients  

 Importance of integrating patient and physician needs within a digital or mobile health platform  

 The challenges associated with designing and developing mobile health platforms for patient-related disease management  

 Technologies need to ‘speak' to each other  

 Early adopters of digital technology  

 Understanding, acceptance and applicability of mobile health  

 Incentivising patients to adhere to mobile health and digital platforms  

 Gamification and novel approaches to mobile health platform development  

 Changing patient behaviours via mobile health and digital platforms: medication adherence, lifestyle factors, monitoring outcomes  

 Non-adherence: increasing burden on healthcare system  

 The mobile health business case: what return can pharmaceutical companies expect for investing resources in mobile health and related digital platforms?  

 Commercial pay-off for digital platforms  

 Opening up new revenue streams  

 Digital platforms that are associated with a medication  

 Brand awareness and brand loyalty 

 Mobile health for data monitoring and data exchange: clinical trials, real-world data, or health outcomes management  

 A wealth of valuable data  

 Big Data  

 Regulators and payers demand real world data  

 Mobile health solutions for clinical trials  

 Cautious steps into the world of digital and mobile health: minimising obstacles and maximising opportunities  

 Regulations on the development of digital and mobile healthcare innovations  

 Developing an evidence base for digital healthcare solutions  

 Should pharmaceutical companies enter the digital platforms arena alone or in partnership?  

 Conclusion  

 Acknowledgements